157 related articles for article (PubMed ID: 31509833)
1. Correlation between Skeletal Muscle Mass and Adverse Events of Neoadjuvant Chemotherapy in Patients with Gastric Cancer.
Matsuura N; Motoori M; Fujitani K; Nishizawa Y; Komatsu H; Miyazaki Y; Miyazaki S; Tomokuni A; Komori T; Iwase K
Oncology; 2020; 98(1):29-34. PubMed ID: 31509833
[TBL] [Abstract][Full Text] [Related]
2. Skeletal Muscle Loss during Neoadjuvant Chemotherapy Is an Independent Risk Factor for Postoperative Infectious Complications in Patients with Advanced Esophageal Cancer.
Motoori M; Fujitani K; Sugimura K; Miyata H; Nakatsuka R; Nishizawa Y; Komatsu H; Miyazaki S; Komori T; Kashiwazaki M; Iwase K; Yano M
Oncology; 2018; 95(5):281-287. PubMed ID: 30149394
[TBL] [Abstract][Full Text] [Related]
3. Clinical Assessment of Sarcopenia and Changes in Body Composition During Neoadjuvant Chemotherapy for Esophageal Cancer.
Miyata H; Sugimura K; Motoori M; Fujiwara Y; Omori T; Yanagimoto Y; Ohue M; Yasui M; Miyoshi N; Tomokuni A; Akita H; Kobayashi S; Takahashi H; Yano M
Anticancer Res; 2017 Jun; 37(6):3053-3059. PubMed ID: 28551644
[TBL] [Abstract][Full Text] [Related]
4. Clinical impact of skeletal muscle mass change during the neoadjuvant chemotherapy period in patients with gastric cancer: An ancillary study of JCOG1002.
Sato R; Tokunaga M; Mizusawa J; Sato Y; Ito S; Takahari D; Sano T; Onaya H; Yoshikawa T; Boku N; Terashima M
World J Surg; 2024 Jan; 48(1):163-174. PubMed ID: 38686798
[TBL] [Abstract][Full Text] [Related]
5. [Effect of neoadjuvant chemotherapy on nutritional status of locally advanced gastric cancer].
Deng G; Qu J; Zhai S; Shi Y; Wang X
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Mar; 21(3):331-335. PubMed ID: 29577223
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant chemotherapy with S-1 and CDDP in advanced gastric cancer.
Kochi M; Fujii M; Kanamori N; Kaiga T; Takahashi T; Kobayashi M; Takayama T
J Cancer Res Clin Oncol; 2006 Dec; 132(12):781-5. PubMed ID: 16804723
[TBL] [Abstract][Full Text] [Related]
7. Clinical utility of bioelectrical impedance analysis in patients with locoregional muscle invasive or metastatic urothelial carcinoma: a subanalysis of changes in body composition during neoadjuvant systemic chemotherapy.
Miyake M; Owari T; Iwamoto T; Morizawa Y; Hori S; Marugami N; Shimada K; Iida K; Ohnishi K; Gotoh D; Tatsumi Y; Nakai Y; Inoue T; Anai S; Torimoto K; Aoki K; Yoneda T; Tanaka N; Fujimoto K
Support Care Cancer; 2018 Apr; 26(4):1077-1086. PubMed ID: 29022158
[TBL] [Abstract][Full Text] [Related]
8. [Prognostic analysis of neoadjuvant chemotherapy for locally advanced gastric cancer with propensity score matching method].
Peng L; Yang W; Zhang Z; Zhi C; Zhou X; Liu H; Hua Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Oct; 21(10):1148-1153. PubMed ID: 30370514
[TBL] [Abstract][Full Text] [Related]
9. Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer.
Tan BH; Brammer K; Randhawa N; Welch NT; Parsons SL; James EJ; Catton JA
Eur J Surg Oncol; 2015 Mar; 41(3):333-8. PubMed ID: 25498359
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemotherapy for gastric cancer. Is it a must or a fake?
Reddavid R; Sofia S; Chiaro P; Colli F; Trapani R; Esposito L; Solej M; Degiuli M
World J Gastroenterol; 2018 Jan; 24(2):274-289. PubMed ID: 29375213
[TBL] [Abstract][Full Text] [Related]
11. Posttherapy nodal status, not graded histologic response, predicts survival after neoadjuvant chemotherapy for advanced gastric cancer.
Fujitani K; Mano M; Hirao M; Kodama Y; Tsujinaka T
Ann Surg Oncol; 2012 Jun; 19(6):1936-43. PubMed ID: 22187120
[TBL] [Abstract][Full Text] [Related]
12. Changes in body composition secondary to neoadjuvant chemotherapy for advanced esophageal cancer are related to the occurrence of postoperative complications after esophagectomy.
Ida S; Watanabe M; Karashima R; Imamura Y; Ishimoto T; Baba Y; Iwagami S; Sakamoto Y; Miyamoto Y; Yoshida N; Baba H
Ann Surg Oncol; 2014 Oct; 21(11):3675-9. PubMed ID: 24793436
[TBL] [Abstract][Full Text] [Related]
13. Skeletal muscle loss after total gastrectomy, exacerbated by adjuvant chemotherapy.
Yamaoka Y; Fujitani K; Tsujinaka T; Yamamoto K; Hirao M; Sekimoto M
Gastric Cancer; 2015 Apr; 18(2):382-9. PubMed ID: 24715254
[TBL] [Abstract][Full Text] [Related]
14. Protocol of a pilot randomized clinical trial to evaluate nutritional support and rehabilitation on prevention of skeletal muscle mass loss during neoadjuvant chemotherapy in patients with esophageal cancer.
Miki Y; Nishi S; Tamura T; Imai T; Nambara M; Fukuoka T; Yoshii M; Toyokawa T; Lee S; Fujii H; Yoshida H; Ikebuchi M; Maeda K
PLoS One; 2024; 19(4):e0302003. PubMed ID: 38635741
[TBL] [Abstract][Full Text] [Related]
15. Survival Benefit of Neoadjuvant Chemotherapy with S-1 Plus Docetaxel for Locally Advanced Gastric Cancer: A Propensity Score-Matched Analysis.
Kano M; Hayano K; Hayashi H; Hanari N; Gunji H; Toyozumi T; Murakami K; Uesato M; Ota S; Matsubara H
Ann Surg Oncol; 2019 Jun; 26(6):1805-1813. PubMed ID: 30977014
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy of neoadjuvant chemotherapy with irinotecan (CPT-11) and nedaplatin followed by radical hysterectomy for locally advanced cervical cancer.
Abou-Taleb HA; Koshiyama M; Matsumura N; Baba T; Yamaguchi K; Hamanishi J; Abiko K; Yamanoi K; Murakami R; Horikawa N; Taha AA; Kitamura S; Konishi I
J Int Med Res; 2016 Apr; 44(2):346-56. PubMed ID: 26831404
[TBL] [Abstract][Full Text] [Related]
17. Loss of skeletal muscle mass during palliative chemotherapy is a poor prognostic factor in patients with advanced gastric cancer.
Park SE; Choi JH; Park JY; Kim BJ; Kim JG; Kim JW; Park JM; Chi KC; Hwang IG
Sci Rep; 2020 Oct; 10(1):17683. PubMed ID: 33077864
[TBL] [Abstract][Full Text] [Related]
18. [A safety analysis in patients treated with oxaliplatin plus S-1 as adjuvant therapy for gastric cancer].
Zhou Y; Huang J; Yang L; Chi Y; Qu T; Lü X; Wang JW
Zhonghua Zhong Liu Za Zhi; 2012 Nov; 34(11):860-4. PubMed ID: 23291138
[TBL] [Abstract][Full Text] [Related]
19. [The efficacy of neoadjuvant chemotherapy with S-1/CDDP (SP) to the patients with large type 3 and type 4 gastric cancer].
Katayanagi S; Nomura T; Sumi T; Suda T; Hoshino S; Ito K; Takagi Y; Tsuchida A; Kawachi S; Shimazu M
Gan To Kagaku Ryoho; 2013 Nov; 40(12):2214-6. PubMed ID: 24394063
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of neoadjuvant chemotherapy with S-1 and cisplatin for stage III gastric cancer: KUGC03.
Okabe H; Hata H; Ueda S; Zaima M; Tokuka A; Yoshimura T; Ota S; Kinjo Y; Yoshimura K; Sakai Y;
J Surg Oncol; 2016 Jan; 113(1):36-41. PubMed ID: 26604064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
